153 related articles for article (PubMed ID: 33347896)
21. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
[TBL] [Abstract][Full Text] [Related]
22. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
[TBL] [Abstract][Full Text] [Related]
23. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
[TBL] [Abstract][Full Text] [Related]
24. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
[TBL] [Abstract][Full Text] [Related]
25. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
26. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.
Welaya K; Loh KP; Messing S; Szuba E; Magnuson A; Mohile SG; Maggiore RJ
J Geriatr Oncol; 2020 Apr; 11(3):523-528. PubMed ID: 31175042
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Martin-Romano P; Ammari S; El-Dakdoukti Y; Baldini C; Varga A; Vuagnat P; Angevin E; Bahleda R; Gazzah A; Champiat S; Michot JM; Postel-Vinay S; Marabelle A; Soria JC; Boige V; Malka D; Ducreux M; Massard C; Hollebecque A
Eur J Cancer; 2020 Sep; 137():117-126. PubMed ID: 32755794
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
29. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors.
Seethapathy H; Rusibamayila N; Chute DF; Lee M; Strohbehn I; Zubiri L; Faje AT; Reynolds KL; Jhaveri KD; Sise ME
Nephrol Dial Transplant; 2021 Dec; 36(12):2241-2247. PubMed ID: 33374011
[TBL] [Abstract][Full Text] [Related]
30. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
32. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
33. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
34. Neurotoxicities associated with immune checkpoint inhibitor therapy.
Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
36. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.
Bae S; Kim YJ; Kim MJ; Kim JH; Yun SC; Jung J; Kim MJ; Chong YP; Kim SH; Choi SH; Kim YS; Lee SO
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34521732
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
Parikh AB; Zhong X; Mellgard G; Qin Q; Patel VG; Wang B; Alerasool P; Garcia P; Leiter A; Gallagher EJ; Clinton S; Mortazavi A; Monk P; Folefac E; Yin M; Yang Y; Galsky M; Oh WK; Tsao CK
Am J Clin Oncol; 2021 Mar; 44(3):114-120. PubMed ID: 33417323
[TBL] [Abstract][Full Text] [Related]
38. Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials.
Fujiwara Y; Kuchiba A; Koyama T; Machida R; Shimomura A; Kitano S; Shimizu T; Yamamoto N
ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32276948
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism.
Mourad D; Azar NS; Eid AA; Azar ST
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672515
[TBL] [Abstract][Full Text] [Related]
40. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]